Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections

被引:25
作者
Cecil, Jane A. [1 ]
Wenzel, Richard P. [1 ]
机构
[1] Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA 23298 USA
关键词
antifungal treatment; Aspergillus; azole; Candida; ergosterol synthesis; fungi; Fusarium; lanosterol; 14; alpha-demethylase; mold; mycoses; pheohyphomycosis; Scedosporium; triazole; voriconazole; yeast; zygomycosis; CELL TRANSPLANT RECIPIENTS; LIPOSOMAL AMPHOTERICIN-B; IN-VITRO ACTIVITIES; CHRONIC PULMONARY ASPERGILLOSIS; TOXIC EPIDERMAL NECROLYSIS; IMMUNOCOMPROMISED PATIENTS; SCEDOSPORIUM-APIOSPERMUM; ANTIFUNGAL THERAPY; UNITED-STATES; BREAKTHROUGH ZYGOMYCOSIS;
D O I
10.1586/EHM.09.13
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Over the last 20 years, the frequency of life-threatening, invasive fungal infections has risen dramatically, corresponding to an increase in the number of immunocompromised patients. Thus, the development of newer, better tolerated, more effective antifungal drugs has become critically important. Voriconazole was the first second-generation triazole to be approved by the US FDA and the EM EA, both in 2002. Voriconazole is currently approved for the treatment of invasive aspergillosis, candidemia, candidal esophagitis and disseminated candidiasis in adults, and serious fungal infections due to Scedosporium apiospermum and Fusarium species. In addition to providing an alternative treatment option for Candida infections and many emerging and refractory invasive fungal infections, voriconazole is currently the treatment of choice for invasive aspergillosis. Voriconazole has excellent in vitro activity against a wide spectrum of yeasts and molds, with only a few notable exceptions. Although it has the potential for some unique and interesting side effects, as well as important drug drug interactions, the use of therapeutic drug monitoring can be used to optimize its efficacy and safety.
引用
收藏
页码:237 / 254
页数:18
相关论文
共 113 条
[81]   Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole [J].
Reis, A ;
Sundmacher, R ;
Tintelnot, K ;
Agostini, H ;
Jensen, HE ;
Althaus, C .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2000, 84 (08) :932-933
[82]   Disseminated phaeohyphomycosis: Review of an emerging mycosis [J].
Revankar, SG ;
Patterson, JE ;
Sutton, DA ;
Pullen, R ;
Rinaldi, MG .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (04) :467-476
[83]   Changing patterns and trends in systemic fungal infections [J].
Richardson, MD .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 56 :5-11
[84]   In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection [J].
Ruhnke, M ;
SchmidtWesthausen, A ;
Trautmann, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (03) :575-577
[85]  
Sambatakou H, 2006, AM J MED, V119
[86]   A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei [J].
Sanati, H ;
Belanger, P ;
Fratti, R ;
Ghannoum, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2492-2496
[87]   Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis [J].
Siwek, GT ;
Dodgson, KJ ;
de Magalhaes-Silverman, M ;
Bartelt, LA ;
Kilborn, SB ;
Hoth, PL ;
Diekema, DJ ;
Pfaller, MA .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (04) :584-587
[88]   Voriconazole therapeutic drug monitoring [J].
Smith, J ;
Safdar, N ;
Knasinski, V ;
Simmons, W ;
Bhavnani, SM ;
Ambrose, PG ;
Andes, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (04) :1570-1572
[89]   Infections due to Aspergillus terreus:: A multicenter retrospective analysis of 83 cases [J].
Steinbach, WJ ;
Benjamin, DK ;
Kontoyiannis, DP ;
Perfect, JR ;
Lutsar, I ;
Marr, KA ;
Lionakis, MS ;
Torres, HA ;
Jafri, H ;
Walsh, TJ .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (02) :192-198
[90]   Bone and joint infection after traumatic implantation of Scedosporium prolificans treated with voriconazole and surgery [J].
Studahl, M ;
Backteman, T ;
Stålhammar, F ;
Chryssanthou, E ;
Petrini, B .
ACTA PAEDIATRICA, 2003, 92 (08) :980-982